Targeting Mitochondrial Dysfunction
Our lead product, Imeglimin, is in Phase 3 development in Japan and has successfully completed Phase 2 development in the U.S. and EU.
View Candidate
Innovative Pipeline of First-In-Class Products
Our candidates are based on disease-modifying mechanisms of action that offer the potential for safer and more effective therapies for type 2 diabetes and NASH.
View Pipeline
Backed by Strong Leadership
Our highly-experienced clinical and regulatory teams possess the know-how and experience to successfully develop products within our pipeline.
Meet Our Team
Latest News
Poxel Announces Updates to its Management Team
LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and…
Read this Press Release: Poxel Announces Updates to its Management TeamPoxel Announces Positive Topline Results for Imeglimin Phase 3 Trial (TIMES 3 36-week) for the Treatment of Type 2 Diabetes in Japan
Imeglimin in combination with insulin was observed to demonstrate consistent and sustained efficacy in the TIMES 3 36-week, open-label extension period These results build upon the positive results from the 16-week…
Read this Press Release: Poxel Announces Positive Topline Results for Imeglimin Phase 3 Trial (TIMES 3 36-week) for the Treatment of Type 2 Diabetes in JapanPoxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019
PXL065 observed to have a favorable safety, tolerability and pharmacokinetic (PK) profile in the Phase 1a trial PXL065 intends to utilize the 505(b)(2) regulatory pathway, which offers the opportunity for a…
Read this Press Release: Poxel Announces Presentation of PXL065 Phase 1a Results at the Liver Meeting® 2019
